Product Description
CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor.
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Phase 1: Breast Cancer|Endometrial Cancer|Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JapicCTI-152791 | P2 |
Terminated |
Oncology Solid Tumor Unspecified |
2017-09-01 |
|
CCLR457X2101 | P1 |
Terminated |
Endometrial Cancer|Lung Cancer|Breast Cancer |
2015-11-12 |
42% |
2014-000316-34 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2015-11-12 |